O'CALLAGHAN BRIAN 4
4 · Bolt Biotherapeutics, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Bolt Biotherapeutics Director Brian O'Callaghan Receives Award
What Happened Brian O'Callaghan, a director of Bolt Biotherapeutics (BOLT), received a derivative award on 2026-06-10: options covering 5,000 shares reported at $0.00 (i.e., a grant/award rather than an open-market purchase). The Form 4 reflecting this grant was filed on 2026-06-11.
Key Details
- Transaction date: 2026-06-10; Form 4 filed: 2026-06-11 (timely).
- Transaction type: Award/Grant of derivative securities (Code A); 5,000 shares @ $0.00.
- Shares owned after transaction: not specified in the provided filing.
- Footnote: options vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting, subject to continuous service; the option vests in full upon a change in control.
- Filing status: appears timely (no late filing flag disclosed).
Context This filing documents a typical director equity grant (an option/award) used for compensation and retention. The award does not represent an immediate market purchase or sale, and vesting conditions mean the shares are not immediately transferable unless accelerated by a change in control.
Insider Transaction Report
Form 4
O'CALLAGHAN BRIAN
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-06-10+5,000→ 5,000 totalExercise: $4.43Exp: 2036-06-09→ Common Stock (5,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Signature
/s/ William P. Quinn, Attorney-in-Fact|2026-06-11